Yosprala FDA Approval History
FDA Approved: Yes (First approved September 14, 2016)
Brand name: Yosprala
Generic name: aspirin and omeprazole
Dosage form: Delayed-Release Tablets
Company: Aralez Pharmaceuticals Inc.
Treatment for: Ischemic Stroke, Prophylaxis, Gastric Ulcer Prophylaxis
Yosprala (aspirin and omeprazole) is a platelet aggregation inhibitor and proton pump inhibitor combination indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.
Development timeline for Yosprala
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.